AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
AVITA Medical, Inc.NASDAQ: RCEL
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $18.9M fell 10.9% year over year, ahead of the -14.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at +20.9% a year.
Context
- Selling, general & admin amounted to 111.6% of revenue in FY2025, down 30.6 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $117.42M (+46.9%) for the fiscal year ending Dec 2026, a step up from the -12.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $18.9M-0.7% QoQ
- Last fiscal yearDec 2025
- $79.91M-12.6% YoY
- LTMMar 2026
- $78.19M-14.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 79.91M USD
- Year-over-year change
- -12.6%
- 4-year CAGR
- +21.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 79.91M | -12.6% |
| FY2024 | 2024-12-31 | 91.39M | +39.3% |
| FY2023 | 2023-12-31 | 65.63M | +45.1% |
| FY2022 | 2022-12-31 | 45.24M | +21.6% |
| FY2021 | 2021-12-31 | 37.21M | — |
Selling, General & Admin vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's LTM Mar 2026 selling, general & admin of $78.19M is the 2nd highest of the 9 companies compared; the peer median is $25.54M.
- Its year-over-year change of -14.1% is the lowest of 9, against a peer median of -4.3%.
- Selling, general & admin amounts to 108.1% of revenue for RCEL, versus a peer median of 171.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.08B | +51937.5% | +914.5% | 391112.6% | |
| LTM Mar 2026 | $78.19M | -14.1% | +20.9% | 108.1% | |
| LTM Mar 2026 | $70.61M | -7.6% | +25.4% | 57.9% | |
| LTM Mar 2026 | $31.78M | -9.7% | -9.1% | 56.8% | |
| LTM Mar 2026 | $26.33M | -2.2% | -17.3% | 171.8% | |
| LTM Mar 2026 | $24.75M | -6.4% | -9.4% | 347.5% | |
| LTM Mar 2026 | $21.42M | +168.1% | — | 20.3% | |
| LTM Mar 2026 | $17.37M | -6.9% | -4.3% | 1736.5% | |
| LTM Mar 2026 | $9.52M | +9.5% | +20.6% | — | |
| Peer median (excluding RCEL) | $25.54M | -4.3% | -4.3% | 171.8% | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.03M | 34.42M | 50.14M | 64.25M | 71.61M |
| Cost of Revenue | 6.1M | 6.04M | 7.78M | 9.09M | 12.79M |
| Gross Profit | 26.92M | 28.38M | 42.36M | 55.16M | 58.82M |
| Gross Margin | 81.5% | 82.4% | 84.5% | 85.8% | 82.1% |
| Research & Development | 15.67M | 13.86M | 20.82M | 20.36M | 20.84M |
| Selling, General & Admin | 37.21M | 45.24M | 65.63M | 91.39M | 79.91M |
| Operating Expenses | 52.04M | 55.89M | 85.02M | 111.75M | 100.75M |
| Depreciation & Amortization | 673K | 568K | 632K | 1.13M | 2.35M |
| EBITDA | (24.4M) | (26.05M) | (33.54M) | (55.3M) | (39.59M) |
| EBITDA Margin | -73.9% | -75.7% | -66.9% | -86.1% | -55.3% |
| Operating Income | (25.12M) | (27.51M) | (42.66M) | (56.59M) | (41.93M) |
| Operating Margin | -76.1% | -79.9% | -85.1% | -88.1% | -58.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 29K | 16K | 1.14M | 5.36M | 5M |
| Other Income / Expenses | 18K | 876K | 7.34M | (5.2M) | (6.64M) |
| Income Before Tax | (25.1M) | (26.63M) | (35.32M) | (61.79M) | (48.58M) |
| Pre-Tax Margin | -76.0% | -77.4% | -70.4% | -96.2% | -67.8% |
| Income Tax Expense | 42K | 36K | 66K | 54K | 11K |
| Net Income | (25.14M) | (26.67M) | (35.38M) | (61.85M) | (48.59M) |
| Net Margin | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% |
| EPS (Basic) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| EPS (Diluted) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| Weighted Avg Shares | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
| Weighted Avg Shares (Diluted) | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.